Exabis Library
Welcome to the e-CCO Library!
OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s Disease: Results from a phase 2 open-label 48-week extension study
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:07 PM by ECCO Administrator
1
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:06 PM by ECCO Administrator
1
OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:04 PM by ECCO Administrator
1
OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP034: The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the eneida registry
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for Moderate to Severe Crohn’s Disease
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:03 PM by ECCO Administrator
1
OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild- moderately active Ulcerative Colitis: A randomised controlled trial
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 1:55 PM by ECCO Administrator
1
OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 1:56 PM by ECCO Administrator
1